DE602006006578D1 - Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen - Google Patents

Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen

Info

Publication number
DE602006006578D1
DE602006006578D1 DE602006006578T DE602006006578T DE602006006578D1 DE 602006006578 D1 DE602006006578 D1 DE 602006006578D1 DE 602006006578 T DE602006006578 T DE 602006006578T DE 602006006578 T DE602006006578 T DE 602006006578T DE 602006006578 D1 DE602006006578 D1 DE 602006006578D1
Authority
DE
Germany
Prior art keywords
chlorine
treatment
prion diseases
guanabenz derivatives
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006006578T
Other languages
English (en)
Inventor
Marc Blondel
Stephane Bach
Didier Vilette
Vincent Beringue
Deborah Tribouillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Recherche Agronomique INRA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Recherche Agronomique INRA filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE602006006578D1 publication Critical patent/DE602006006578D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602006006578T 2006-10-04 2006-10-04 Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen Active DE602006006578D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291548A EP1908465B1 (de) 2006-10-04 2006-10-04 Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen

Publications (1)

Publication Number Publication Date
DE602006006578D1 true DE602006006578D1 (de) 2009-06-10

Family

ID=37836911

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006006578T Active DE602006006578D1 (de) 2006-10-04 2006-10-04 Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen

Country Status (7)

Country Link
US (1) US20110251428A1 (de)
EP (2) EP1908465B1 (de)
JP (1) JP5186503B2 (de)
AT (1) ATE429910T1 (de)
CA (1) CA2664959A1 (de)
DE (1) DE602006006578D1 (de)
WO (1) WO2008041134A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083397A1 (en) 2010-12-22 2012-06-28 Silvestre Labs Químia E Farmaceutica Ltda. Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
WO2016162689A1 (en) 2015-04-08 2016-10-13 Medical Research Council Inhibitors and their uses
US11224586B2 (en) * 2016-10-18 2022-01-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis
US20210177814A1 (en) 2018-05-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975533A (en) * 1970-04-29 1976-08-17 Shell Oil Company Therapeutic agents
US3816531A (en) * 1970-07-01 1974-06-11 American Home Prod (2,6-disubstituted benzylidene)amino guanidines and related compounds
US6413962B1 (en) * 1988-05-02 2002-07-02 N. Eric Naftchi Guanidino compounds effective as anesthetics
AU5636300A (en) * 1999-06-25 2001-01-31 Avicena Group, Inc. Use of creatine or creatine analogs for the prevention and treatment of transmissible spongiform encephalopathies
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
WO2003006426A1 (en) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Aromatic guanylhydrazones as effective compounds against neurodiseases
JP2006502744A (ja) * 2002-10-18 2006-01-26 ノバルティス・フォルシュングスシュティフトゥング・ツヴァイクニーダーラッスング・フリードリッヒ・ミーシェー・インスティトゥート・フォー・バイオメディカル・リサーチ 肥満処置のためのｓ６キナーゼ活性のモジュレーション
FR2846009B1 (fr) * 2002-10-18 2007-10-12 Centre Nat Rech Scient Criblage de molecules a activite anti-prion:kits, methodes et molecules criblees
FR2893844B1 (fr) * 2005-11-28 2008-02-01 Centre Nat Rech Scient Utilisation du guanabenz et de ses derives pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
EP1908464A1 (de) * 2006-10-04 2008-04-09 Centre National De La Recherche Scientifique (Cnrs) Verwendung von Chlorine-Guanabenz-Deriaten zur Behandlung von Polyglutaminexpansionskrankheiten

Also Published As

Publication number Publication date
JP2010505815A (ja) 2010-02-25
WO2008041134A3 (en) 2008-06-19
US20110251428A1 (en) 2011-10-13
CA2664959A1 (en) 2008-04-10
EP2076253A2 (de) 2009-07-08
EP1908465A1 (de) 2008-04-09
WO2008041134A2 (en) 2008-04-10
JP5186503B2 (ja) 2013-04-17
ATE429910T1 (de) 2009-05-15
EP1908465B1 (de) 2009-04-29

Similar Documents

Publication Publication Date Title
EA201000050A1 (ru) Замещенные бициклолактамные соединения
ATE548032T1 (de) Verwendung von chlorguanabenzderivaten zur behandlung von mit polyglutaminexpansion assoziierten erkrankungen
ATE517882T1 (de) Chinolinderivate
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
DK2212283T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
NO20082096L (no) Azaindol-2-karboksamidderivativer
ATE547417T1 (de) Dihydropyrimidinverbindungen und ihre verwendungen bei der herstellung von medikamenten zur behandlung und prävention antiviraler krankheiten
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
DK2212282T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
MA32505B1 (fr) 5-alcynyl-pyrimidines
CY1114400T1 (el) Θεραπευτικες εφαρμογες των παραγωγων κιναζολινεδιονης
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
DE602006006578D1 (de) Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen
EA200801425A1 (ru) Диазепиноны
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
EA200700707A1 (ru) Производные 2-ациламинотиазола
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition